Commercial vaccines used in poultry, cattle, and aquaculture

Currently, maintaining or expanding on these successes poses a significant challenge for the global biopharmaceutical industry. Meeting the high demand for vaccines tailored to the specificities of each pathogen and species requires robust production systems capable of producing in a stable and high yielding manner (9, 10). There are several technological platforms (traditional or modern) available for this purpose, as well as different options for obtaining effective, stable, and safe vaccines (2). Knowing the best option for each species and infectious agent in advance is critical for the industry in this highly diverse and complex environment. It will allow manufacturers to make the best decisions with a minimal risk of failure, quickly enter the market, and optimally take advantage of all available resources. Based on these facts, an investigation was conducted with the aim of comparing global trends in the manufacture and marketing of avian, bovine, and fish vaccines.

当前，维持或拓展上述成果对全球生物制药行业而言是一项重大挑战。为满足针对每种病原体与物种特性定制的疫苗的高需求量，需要构建具备稳定、高产生产能力的稳健生产体系(9, 10)。目前已有多种（传统与现代）技术平台可用于该场景，同时也存在多条可制备高效、稳定且安全疫苗的技术路径(2)。在这一高度多元且复杂的行业环境中，提前明确针对各物种与传染性病原体的最优技术方案，对行业而言至关重要。此举可帮助制造商以最低失败风险做出最优决策，快速切入市场，并最大化利用所有可用资源。基于上述背景，本研究开展了一项调查，旨在对比禽用、牛用及鱼用疫苗的全球生产与营销趋势。